

COVID-19 CLINICAL TRIALS



These are the initial findings from Expert System's Artificial Intelligence platform, **Clinical Research Navigator (CRN)**, which collects biomedical research information from official reports and studies published worldwide.



The **United States** leads the way with **more than 300 current studies**.



The majority of trials in the US are sponsored by the National Institute of Allergy and Infectious Diseases.




More than **1,700** COVID-19 Clinical Trials Registered Worldwide

ANTIMALARIALS



Most clinical trials are currently focused on antimalarial drugs, including hydroxychloroquine, which account for **20%** of the total studies. These types of drugs block the entry of the virus into cells, slowing down its progression.

- hydroxychloroquine (62%)
- hydroxychloroquine sulfate (20%)
- chloroquine (11%)
- chloroquine phosphate (4%)
- ivermectin (2%)
- others (1%)



ANTIVIRALS



Antivirals, such as the drug Remdesivir, represent **13%** of studies. These drugs inhibit the replication of the virus gene, slowing down its spread and reducing the complications of the disease.




- ritonavir (23%)
- lopinavir (20%)
- ritonavir and lopinavir (22%)
- remdesivir (18%)
- favipiravir (8%)
- oseltamivir (6%)
- others (3%)

ANTINEOPLASTIC AND IMMUNOMODULATORY AGENTS



Studies for anti-neoplastic and immunomodulatory agents represent **10%** of current studies. These agents attempt to modify the immune response caused by the virus.



- baricitinib (9%)
- tocilizumab (37%)
- sarilumab (13%)
- baricitinib (7%)
- ruxolitinib (12%)
- anakinra (10%)
- interferon beta1a (6%)
- others (6%)



ANTIBIOTICS



7% of studies are focused on antibiotics, such as azithromycin.

CORTICOSTEROIDS

6% of studies are on drugs with corticosteroids, which serve to modulate the immune and inflammatory response.



- methylprednisolone and derivatives (28%)
- prednisolone and derivatives (30%)
- dexamethasone (11%)
- hydrocortisone and derivatives (16%)
- prednisone (3%)
- budesonide (7%)
- others (5%)



ANTICOAGULANTS, ANTIAGGREGANTS, PLASMA

4% of studies are for anticoagulants and antiaggregants, which are used to prevent or treat thrombotic phenomena caused by SARS-CoV-2.

3% of studies are focused on the plasma of patients who have recovered from the virus, to study the potential of antibodies to neutralize it.



A VACCINE



More than **30** clinical trials for a COVID-19 vaccine are under way in the United Kingdom, China, the United States and other countries.

About Clinical Research Navigator



Clinical Research Navigator is a single platform where biomedical research scientists can discover insights to drive their research and support discovery of therapies for COVID-19 and other diseases.

FOR MORE INFORMATION VISIT WWW.EXPERTSYSTEM.COM

Disclaimer – The analysis by Expert System is not intended to provide scientific guidelines about diagnosis, treatments or preventions of any disease. While the data collected with our AI-based tool has been checked with a team of experts, the unique intent of our analysis is to offer some insight on the nature and number of published studies and registered clinical trials related to COVID-19 worldwide.